Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567354 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)
A Phase 1 study, sponsored by Ensysce Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05567354 is a Phase 1 study that has completed, run by Ensysce Biosciences. The registered enrollment target is 27 participants.
The verdict
NCT05567354, a Phase 1 study, has completed, sponsored by Ensysce Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
Interventions
- OTHER Placebo
- DRUG Oxycodone
- DRUG PF614
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567354
The ClinicalTrials.gov registry entry for NCT05567354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensysce Biosciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05567354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567354 about?
NCT05567354 is a clinical study titled "A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)". The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
What is the current status of trial NCT05567354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2022-06-10. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05567354?
The interventions under investigation include: Placebo (OTHER), Oxycodone (DRUG), PF614 (DRUG).
Who is sponsoring clinical trial NCT05567354?
This trial is sponsored by Ensysce Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.